Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs
Roche and Evotec AG announced that they have formed an alliance to jointly discover and develop compounds against a target for CNS diseases and other indications. Leveraging the expertise developed by Evotec on this target, and as part of their CNS drug discovery focus, Evotec and Roche will collaborate to identify inhibitors involved in the potential treatment of a range of diseases. Both companies believe that this target is of high priority and that partnering their respective drug discovery efforts and expertise will bring about the successful and timely discovery of new drugs.
Roche and Evotec will jointly progress projects up to clinical development, at which stage Roche will have exclusive rights to the development of the drug candidates. In return, Evotec will be eligible to receive milestone payments that could exceed 100 million Euros in total, plus royalties on the sale of any products. If Roche does not exercise these opt-in rights, Evotec will have the right to opt-in, making adjusted payments to Roche.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.